---
document_datetime: 2023-09-21 18:47:51
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/nevanac-epar-procedural-steps-taken-authorisation_en.pdf
document_name: nevanac-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 1.0910219
conversion_datetime: 2025-12-18 20:23:07.457195
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Alcon  Laboratories  (UK)  Ltd.  submitted  on  18  December  2006  an  application  for Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  NEVANAC,  through  the centralised procedure under Article 3(2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 27 June 2007.

The legal basis for this application refers to:

- A - Centralised / Article 8(3) / New active substance.

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application

## Licensing status:

NEVANAC has been given a Marketing Authorisation in the following countries outside the EEA:

USA

19 August 2005

Argentina

19 January 2006

Aruba

31 January 2006

Chile

31 March 2006

Guatemala

19 July 2006

Kenya

01 November 2006

Mexico

26 September 2006

Nicaragua

06 September 2006

Surinam

05 January 2006

Trinidad and Tobago

17 January 2006

Uruguay

04 October 2006

Venezuela

17 August 2006

A new application was filed in the following countries:

| New Zealand          | 22 May 2006       |
|----------------------|-------------------|
| Brazil               | 30 September 2005 |
| China                | 31 March 2006     |
| Columbia             | 01 August 2005    |
| Costa Rica           | 30 June 2006      |
| Dominican Republic   | 20 September 2006 |
| El Salvador          | 21 August 2006    |
| Honduras             | 17 May 2006       |
| Hong Kong            | 23 September 2005 |
| Kuwait               | 28 November 2005  |
| Panama               | 19 July 2006      |
| Paraguay             | 13 November 2006  |
| Serbia               | 12 December 2005  |
| Taiwan               | 31 January 2006   |
| Thailand             | 19 December 2005  |
| Turkey               | 17 November 2006  |
| United Arab Emirates | 23 April 2006     |
| Vietnam              | 07 October 2006   |

<div style=\"page-break-after: always\"></div>

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 18 December 2006.
- The Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  18  April 2007  (Annex  1).  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 17 April 2007.
- The procedure started on 24 January 2007.
- During  the  meeting  on  21-24  May  2007,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 24 May 2007.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 5 July 2007.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 29 August 2007.
- During the CHMP meeting on 17-20 September 2007, the CHMP agreed on a list of outstanding issues to be addressed in writing and by the applicant.
- The applicant submitted  written  explanations  to  the  CHMP  List  of  Outstanding  Issues  on  20 September 2007.
- The  Rapporteurs  circulated  the  Joint  Assessment  Report  on  the  CHMP  List  of  Outstanding Issues to all CHMP members on 8 October 2007.
- During  the  meeting  on  16-18  October  2007,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting  a  Marketing  Authorisation  for  NEVANAC  on  18  October  2007.  The  applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 10 October 2007.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 11 December 2007.